Top Private Equity News, Member Posts, Managed Futures Daily Indices and more!

2yrs ago Private Equity privateequitywire Views: 245

Kester Capital backs MBO of Rephine

Submitted 15/10/2021 - 9:34am

Buyout specialist Kester Capital (Kester), has invested in Rephine, a provider of Good Manufacturing/Clinical Practice (GMP/GCP) audits and regulatory consulting services to the pharmaceutical industry.

The investment represents Kester’s fourth investment in the Life Sciences sector, and the fourth investment out of its latest fund, Kester Capital II, which closed at its hard cap in August 2020. It also comes at a time of significant positive momentum for Kester, which recently exited Frontier Medical (netting a 3.4x return for its investors), completed two bolt-on acquisitions, and made two hires into its investment team.
 
Headquartered in Stevenage, and with offices in India and Turkey, Rephine is a fast-growing business that has pioneered a differentiated approach to GMP/GCP auditing through its audit library model. This innovative solution addresses common auditee and customer pain points caused by increasingly time-consuming and onerous auditing requirements. 
 
With pharmaceutical supply chains and regulations continuing to grow in complexity, Rephine is well positioned to benefit from these strong market tailwinds. This new partnership with Kester will allow Rephine to invest in growing its audit library and broadening its service offering into other GxP audit areas.
 
Following the acquisition, Adam Sherlock, an experienced life science senior executive, will join the business as CEO, taking over from retiring CEO Rino Coladangelo. In addition, Maureen Coleman, who has held several executive, NED and Chair roles in the life sciences sector, will join as Chair.
 
Adam Sherlock, incoming CEO, says: “This deal is an important and significant milestone for Rephine, and we are delighted to be partnering with Kester Capital. Rephine has huge potential for growth, and I am looking forward to leading the organisation as we move into this next phase.”
 
Rino Coladangelo, outgoing CEO, says: “I am proud to have led Rephine to this point and am pleased to be handing over to Adam, Maureen and the Kester team. I am confident their experience and expertise, supported by the great existing team, will take Rephine to the next level.”
 
Adam Maidment, Managing Partner of Kester Capital, says: “Rephine provides an invaluable service to its auditees and customers through its differentiated audit library model. We are delighted to be partnering with Adam, Maureen and the existing management team to grow the business organically and through acquisition.”

Like this article? Sign up to our free newsletter Author Profile Related Topics Deals & Transactions Healthcare & Life Sciences Investments

Today's Private Equity Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.